Last updated: July 22, 2024
Sponsor: Eastern Switzerland University of Applied Sciences
Overall Status: Active - Recruiting
Phase
N/A
Condition
Scleroderma
Heart Disease
Cardiovascular Disease
Treatment
Oxygen
Clinical Study ID
NCT06174207
RehaExO2
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- We will include male and female lung disease patients undergoing pulmonaryrehabilitation: aged ≥ 18 years; stable condition > 3 weeks (e.g. no exacerbations);resting oxygen saturation (SpO2) ≥ 88% and exercise induced hypoxemia defined by afall in SpO2 by ≥ 4% during a 6-minute walking test (6MWT); informed consent asdocumented by signature.
Exclusion
Exclusion Criteria:
- Severe daytime resting hypoxemia (SpO2 < 88% or partial pressure of oxygen (PaO2) < 8 kPa); unstable condition requiring adaptation of pharmacologic and other treatmentmodalities or requirement of intensive care or relevant severe concomitant disease;inability to follow the procedures of the study, e.g. due to language problems,psychological disorders, neurological or orthopedic problems with walking disabilityor inability to ride a bicycle; women who are pregnant or breast feeding; enrolmentin another clinical trial with active treatment.
Study Design
Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Oxygen
Phase:
Study Start date:
January 24, 2024
Estimated Completion Date:
April 30, 2025
Connect with a study center
Kantonsspital Winterthur
Winterthur, Zürich 8400
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.